2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2724
    Purine nucleoside phosphorylase, Microorganism 9030-21-1
    Purine nucleoside phosphorylase, Microorganism (PNP) is a key enzyme in purine metabolism, which is involved in the purine rescue pathway. The deficiency of Purine nucleoside phosphorylase resulted in impaired T cell function. In the presence of inorganic orthophosphate as the second substrate, Purine nucleoside phosphorylase catalyzes the breaking of the glycosidic bond between ribose and deoxyribonucleoside to generate purine base and ribose (deoxyribose) -1-phosphate.
    Purine nucleoside phosphorylase, Microorganism
  • HY-P2752
    Lipoprotein lipase, Pseudomonas sp 9004-02-8
    Lipoprotein lipase, Pseudomonas sp (LPL) is a multifunctional enzyme from adipose tissue, heart and skeletal muscle, islets and macrophages. Lipoprotein lipase promotes normal lipoprotein metabolism, delivery and utilization of tissue-specific substrates. Lipoprotein lipase catalyzes the rate-limiting step of lipids in blood circulation.
    Lipoprotein lipase, Pseudomonas sp
  • HY-P2932
    Cholecystokinin 9011-97-6 98.16%
    Cholecystokinin is a peptide hormone. Cholecystokinin, as a hunger suppressant, inhibits food intake and stimulates the digestion of fat and protein. Cholecystokinin can be used for the research of gastrointestinal system.
    Cholecystokinin
  • HY-P3280
    γ-Glu-Gly 1948-29-4 98.0%
    γ-Glu-Gly, a γ-glutamyl dipeptide, is a human lipid metabolite.γ-Glu-Gly has a similar structure to GABA (γ-aminobutyric acid) and can act as an antagonist of excitatory amino acids.
    γ-Glu-Gly
  • HY-P4776
    Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27) 202463-00-1 98.01%
    Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27), a vasoactive intestinal peptide (VIP), is a VIP1 antagonist.
    Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27)
  • HY-109165
    Acoramidis 1446711-81-4 98.47%
    Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) is used in the study for transthyretin amyloidosis.
    Acoramidis
  • HY-110095
    (±)-CPSI-1306 1309793-47-2 ≥98.0%
    (±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor (MIF).
    (±)-CPSI-1306
  • HY-111346
    1-Linoleoyl Glycerol 2277-28-3 99.52%
    1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
    1-Linoleoyl Glycerol
  • HY-113262
    8-Hydroxyguanosine 3868-31-3 99.93%
    8-Hydroxyguanosine, an oxidized nucleoside, is a marker of RNA oxidative damage and oxidative stress. 8-Hydroxyguanosine stimulates proliferation and differentiation of murine B cells with immunostimulatory activity. 8-Hydroxyguanosine is promising for research of Alzheimer’s disease and Down’s syndrome.
    8-Hydroxyguanosine
  • HY-113380
    (S)-β-Aminoisobutyric acid 4249-19-8 ≥98.0%
    (S)-β-Aminoisobutyric acid is an orally active S-isomer of β-Aminoisobutyric acid (HY-W012974). (S)-β-Aminoisobutyric acid can be produced through the catabolism of thymine and valine. (S)-β-Aminoisobutyric acid reduces apoptosis and increases the ratio of p-AMPK. (S)-β-Aminoisobutyric acid has cardioprotective effects. (S)-β-Aminoisobutyric acid is associated with acute aerobic exercise.
    (S)-β-Aminoisobutyric acid
  • HY-117095
    4-Methylumbelliferyl oleate 18323-58-5 99.58%
    4-Methylumbelliferyl oleate is a fluorogenic substrate for acid and alkaline lipases. 4-Methylumbelliferyl oleate is cleaved by lipases, liberating 4-Methylumbelliferyl (Ex/Em=320/450 nm).
    4-Methylumbelliferyl oleate
  • HY-118930
    MK-0493 455956-93-1 99.43%
    MK-0493 is an orally active melanocortin-4 receptor (MC4R) agonist. MK-0493 reduces food intake, suppresses weight gain, elevates blood pressure at high doses, and exhibits preclinical erectile regulatory activity. MK-0493 can be used in research related to obesity.
    MK-0493
  • HY-120602
    WWL229 1338575-28-2 99.49%
    WWL229 is a selective inhibitor of carboxylesterase 3 (CES3) with an IC50 1.94 μM. WWL229 attenuates LPS (HY-D1056)-induced pro-inflammatory cytokine mRNA levels, inhibits lipolysis and adipose thermogenesis, impairs mitochondrial function, and promotes lipid storage. WWL229 can be used for the research of obesity, insulin resistance, type 2 diabetes, and lung inflammation.
    WWL229
  • HY-125254
    LEI110 2313525-90-3 99.72%
    LEI110 is a potent, selective and cell-permeable pan-inhibitor of the HRASLS family of thiol hydrolases. LEI110 inhibits PLA2G16, HRASLS2, RARRES3 and iNAT, with pIC50 values of 7.0, 6.8, 6.8, and 7.6, respectively. LEI110 reduces cellular arachidonic acid levels and oleic acid-induced lipolysis in HepG2 cells.
    LEI110
  • HY-126996
    Triiodothyronine sulfate 31135-55-4 98.80%
    Triiodothyronine sulfate is the main metabolite of thyroid hormone triiodothyronine (T3). Triiodothyronine is an active form of thyroid hormone, which binds to β1 thyroid hormone receptor (TRβ1), and activates its activity.
    Triiodothyronine sulfate
  • HY-13771R
    Ursodeoxycholic acid (Standard) 128-13-2 99.83%
    Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
    Ursodeoxycholic acid (Standard)
  • HY-14650R
    DHEA (Standard) 53-43-0 99.31%
    DHEA (Prasterone) (Standard) is the analytical standard of DHEA. This product is intended for research and analytical applications. DHEA is a steroid hormone.
    DHEA (Standard)
  • HY-148814
    BI-3231 2894848-07-6 99.83%
    BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.
    BI-3231
  • HY-149334
    ZLD115 2980653-93-6 99.87%
    ZLD115 (compound 44) is a FB23-derivated inhibitor of Fat Mass and Obesity-associated Protein (FTO). ZLD115 is an antileukemic agent, exhibiting antiproliferative activity against leukemic cell lines.
    ZLD115
  • HY-152221
    PCSK9-IN-10 368434-98-4 98.89%
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
    PCSK9-IN-10
Cat. No. Product Name / Synonyms Application Reactivity